Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adrixetinib - Qurient Therapeutics

Next Previous
Drug Profile

Adrixetinib - Qurient Therapeutics

Alternative Names: Axl/Mer/CSF1R triple Inhibitor; Q-702

Latest Information Update: 13 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Lead Discovery Center; The Max Planck Institute of Biochemistry; Vichem Chemie
  • Developer Merck & Co; Qurient Co
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Macrophage colony-stimulating factor receptor antagonists; Proto-oncogene protein c-mer inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Acute myeloid leukaemia; Haematological malignancies
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 23 Dec 2025 Qurient completes a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04648254)
  • 27 Aug 2025 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (PO) (NCT06712810)
  • 22 Aug 2025 Qurient plans a phase I trial for Graft versus host disease (Treatment-experienced) in Spain (PO) in November 2025 (NCT07138196)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top